Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Embark Laboratories
Copenhagen, Denmark
- Ownership
- Private
- Development stage
- Other
01
Overview
Embark Laboratories developed a novel target for appetite suppression, energy expenditure, and improved insulin sensitivity; its lead metabolic program was acquired by Novo Nordisk for further development targeting obesity and related disorders[1][2][3].
- Therapeutic areas
- CardiovascularEndocrinology
- Modalities
- Small molecule
- Industry
- Biotech
02
Partnerships
Novo Nordisk (acquirer and R&D collaboration)BioInnovation InstituteUniversity of CopenhagenNovo Nordisk FoundationInnovation Fund Denmark
Beyond the preview
Go deeper on Embark Laboratories.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Embark Laboratories.